标题
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
作者
关键词
-
出版物
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-12-24
DOI
10.1111/cei.13255
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes
- (2018) Cynae Johnson et al. CLINICAL THERAPEUTICS
- Atezolizumab for the treatment of breast cancer
- (2018) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene
- (2018) Kristin Nicole Berger et al. GENE
- Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer
- (2018) Xue Xiao et al. GYNECOLOGIC ONCOLOGY
- Major clinical research advances in gynecologic cancer in 2017
- (2018) Dong Hoon Suh et al. Journal of Gynecologic Oncology
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer
- (2018) Gemma L. Owens et al. JOURNAL OF IMMUNOTHERAPY
- Pembrolizumab-induced acute thrombosis
- (2018) Kei Kunimasa et al. MEDICINE
- Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
- (2018) Ioannis Zerdes et al. ONCOGENE
- P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling
- (2018) Luiz Gustavo de Almeida Chuffa et al. Journal of Ovarian Research
- BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
- (2018) Verena Wieser et al. Oncotarget
- Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment
- (2018) Qiang Su et al. Journal of Cancer
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
- (2018) Young Kwang Chae et al. Journal for ImmunoTherapy of Cancer
- Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
- (2018) Klaus Pietzner et al. Journal of Gynecologic Oncology
- Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
- (2018) Curtis McCloskey et al. Cancers
- Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
- (2018) Maureen L. Drakes et al. Cancers
- Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors
- (2017) Chelsea E. Gottlieb et al. GYNECOLOGIC ONCOLOGY
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
- (2017) Xinxin Zhu et al. Journal of Gynecologic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- PD-1 checkpoint inhibition: Toxicities and management
- (2017) Andrew W. Hahn et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
- (2017) Naziheh Assarzadegan et al. VIRCHOWS ARCHIV
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)
- (2016) J.R. Infante et al. ANNALS OF ONCOLOGY
- The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
- (2016) Ivo Meinhold-Heerlein et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
- (2016) Taner Korkmaz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting the programmed cell death-1 pathway in breast and ovarian cancer
- (2016) Leisha A. Emens et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- PARP inhibitors in the ovarian cancer therapy
- (2016) Maksymilian Kruczała et al. Ginekologia Polska
- The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review
- (2016) Xinxin Zhu et al. GYNECOLOGIC ONCOLOGY
- Specific immunotherapy in ovarian cancer: a systematic review
- (2016) Soroush Alipour et al. Immunotherapy
- Immune checkpoint inhibition in ovarian cancer
- (2016) Junzo Hamanishi et al. INTERNATIONAL IMMUNOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
- (2016) Fenne L. Komdeur et al. Oncotarget
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- The PD-1/PD-Ls pathway and autoimmune diseases
- (2014) Suya Dai et al. CELLULAR IMMUNOLOGY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Checkpoint inhibitors in immunotherapy of ovarian cancer
- (2014) Dong-hui Wang et al. TUMOR BIOLOGY
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
- (2014) Maria Muccioli et al. Frontiers in Immunology
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
- (2013) J. R. Webb et al. CLINICAL CANCER RESEARCH
- Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
- (2013) Min Dai et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now